The complement system and antibody-mediated transplant rejection

Journal of Immunology

Volumn 195, Issue 12, 2015, Pages 5525-5531

  Stites, Erik ^a   Le Quintrec, Moglie ^b   Thurman, Joshua M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; ANTIBODY; COMPLEMENT;

ALLOGRAFT; ANTIBODY MEDIATED REJECTION; ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; ENDOTHELIUM INJURY; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; INFLAMMATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE INJURY; ANIMAL; IMMUNOLOGY; ISCHEMIA; METABOLISM; ORGAN TRANSPLANTATION;

ANIMALS; ANTIBODIES; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; ISCHEMIA; ORGAN TRANSPLANTATION;

EID: 84958292394     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501686     Document Type: Review

References (107)

1. Everly, M. J., J. J. Everly, L. J. Arend, P. Brailey, B. Susskind, A. Govil, A. Rike, P. Roy-Chaudhury, G. Mogilishetty, R. R. Alloway, et al. 2009. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9: 1063-1071.
2. El Ters, M., J. P. Grande, M. T. Keddis, E. Rodrigo, B. Chopra, P. G. Dean, M. D. Stegall, and F. G. Cosio. 2013. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am. J. Transplant. 13: 2334-2341.
3. Nair, N., T. Ball, P. A. Uber, and M. R. Mehra. 2011. Current and future challenges in therapy for antibody-mediated rejection. J. Heart Lung Transplant. 30: 612-617.
4. Einecke, G., B. Sis, J. Reeve, M. Mengel, P. M. Campbell, L. G. Hidalgo, B. Kaplan, and P. F. Halloran. 2009. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am. J. Transplant. 9: 2520-2531.
5. Sellarés, J., D. G. de Freitas, M. Mengel, B. Sis, L. G. Hidalgo, A. J. Matas, B. Kaplan, and P. F. Halloran. 2011. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am. J. Transplant. 11: 489-499.
6. El-Zoghby, Z. M., M. D. Stegall, D. J. Lager, W. K. Kremers, H. Amer, J. M. Gloor, and F. G. Cosio. 2009. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9: 527-535.
7. Everly, M. J., L. M. Rebellato, C. E. Haisch, M. Ozawa, K. Parker, K. P. Briley, P. G. Catrou, P. Bolin, W. T. Kendrick, S. A. Kendrick, et al. 2013. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 95: 410-417.
8. Cravedi, P., and P. S. Heeger. 2014. Complement as a multifaceted modulator of kidney transplant injury. J. Clin. Invest. 124: 2348-2354.
9. Haas, M., B. Sis, L. C. Racusen, K. Solez, D. Glotz, R. B. Colvin, M. C. Castro, D. S. David, E. David-Neto, S. M. Bagnasco, et al. 2014. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 14: 272-283.
10. Colvin, R. B. 2007. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 18: 1046-1056.
11. Zou, Y., P. Stastny, C. Süsal, B. Döhler, and G. Opelz. 2007. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 357: 1293-1300.
12. Jackson, A. M., T. K. Sigdel, M. Delville, S. C. Hsieh, H. Dai, S. Bagnasco, R. A. Montgomery, and M. M. Sarwal. 2015. Endothelial cell antibodies associated with novel targets and increased rejection. J. Am. Soc. Nephrol. 26: 1161-1171.
13. Patel, R., and P. I. Terasaki. 1969. Significance of the positive crossmatch test in kidney transplantation. N. Engl. J. Med. 280: 735-739.
14. Gebel, H. M., R. S. Liwski, and R. A. Bray. 2013. Technical aspects of HLA antibody testing. Curr. Opin. Organ Transplant. 18: 455-462.
15. Terasaki, P. I. 2003. Humoral theory of transplantation. Am. J. Transplant. 3: 665-673.
16. Halloran, P. F., J. Schlaut, K. Solez, and N. S. Srinivasa. 1992. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 53: 550-555.
17. Trpkov, K., P. Campbell, F. Pazderka, S. Cockfield, K. Solez, and P. F. Halloran. 1996. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading schema. Transplantation 61: 1586-1592.
18. Kobashigawa, J., M. G. Crespo-Leiro, S. M. Ensminger, H. Reichenspurner, A. Angelini, G. Berry, M. Burke, L. Czer, N. Hiemann, A. G. Kfoury, et al; Consensus Conference Participants. 2011. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30: 252-269.
19. Wallace, W. D., S. S. Weigt, and C. F. Farver. 2014. Update on pathology of antibody-mediated rejection in the lung allograft. Curr. Opin. Organ Transplant. 19: 303-308.
20. Feucht, H. E., E. Felber, M. J. Gokel, G. Hillebrand, U. Nattermann, C. Brockmeyer, E. Held, G. Riethmüller, W. Land, and E. Albert. 1991. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin. Exp. Immunol. 86: 464-470.
21. Feucht, H. E., H. Schneeberger, G. Hillebrand, K. Burkhardt, M. Weiss, G. Riethmüller, W. Land, and E. Albert. 1993. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int. 43: 1333-1338.
22. Racusen, L. C., R. B. Colvin, K. Solez, M. J. Mihatsch, P. F. Halloran, P. M. Campbell, M. J. Cecka, J. P. Cosyns, A. J. Demetris, M. C. Fishbein, et al. 2003. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 3: 708-714.
23. Colvin, M. M., J. L. Cook, P. Chang, G. Francis, D. T. Hsu, M. S. Kiernan, J. A. Kobashigawa, J. Lindenfeld, S. C. Masri, D. Miller, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Radiology and Intervention; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Surgery and Anesthesia. 2015. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation 131: 1608-1639.
24. Duncan, A. R., and G. Winter. 1988. The binding site for C1q on IgG. Nature 332: 738-740.
25. Bindon, C. I., G. Hale, M. Brüggemann, and H. Waldmann. 1988. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J. Exp. Med. 168: 127-142.
26. Hughes-Jones, N. C., and B. Gardner. 1979. Reaction between the isolated globular sub-units of the complement component C1q and IgG-complexes. Mol. Immunol. 16: 697-701.
27. Diebolder, C. A., F. J. Beurskens, R. N. de Jong, R. I. Koning, K. Strumane, M. A. Lindorfer, M. Voorhorst, D. Ugurlar, S. Rosati, A. J. Heck, et al. 2014. Complement is activated by IgG hexamers assembled at the cell surface. Science 343: 1260-1263.
28. Blom, A. M., B. O. Villoutreix, and B. Dahlbäck. 2004. Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol. Immunol. 40: 1333-1346.
29. Chen Song, S., S. Zhong, Y. Xiang, J. H. Li, H. Guo, W. Y. Wang, Y. L. Xiong, X. C. Li, S. Chen Shi, X. P. Chen, and G. Chen. 2011. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am. J. Transplant. 11: 2057-2066. doi:10.1111/j.1600-6143.2011.03646.x
30. Collard, C. D., C. Bukusoglu, A. Agah, S. P. Colgan, W. R. Reenstra, B. P. Morgan, and G. L. Stahl. 1999. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am. J. Physiol. 276: C450-C458.
31. Ollert, M. W., K. David, R. Bredehorst, and C. W. Vogel. 1995. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J. Immunol. 155: 4955-4962.
32. Gershov, D., S. Kim, N. Brot, and K. B. Elkon. 2000. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192: 1353-1364.
33. Trouw, L. A., A. A. Bengtsson, K. A. Gelderman, B. Dahlbäck, G. Sturfelt, and A. M. Blom. 2007. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J. Biol. Chem. 282: 28540-28548.
34. Renner, B., D. Strassheim, C. R. Amura, L. Kulik, D. Ljubanovic, M. J. Glogowska, K. Takahashi, M. C. Carroll, V. M. Holers, and J. M. Thurman. 2010. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J. Immunol. 185: 4393-4400.
35. Iwasaki, K., Y. Miwa, H. Ogawa, S. Yazaki, M. Iwamoto, T. Furusawa, A. Onishi, T. Kuzuya, M. Haneda, Y. Watarai, et al. 2012. Comparative study on signal transduction in endothelial cells after anti-A/B and human leukocyte antigen antibody reaction: implication of accommodation. Transplantation 93: 390-397.
36. Cole, D. S., and B. P. Morgan. 2003. Beyond lysis: how complement influences cell fate. Clin. Sci. 104: 455-466.
37. Jane-Wit, D., T. D. Manes, T. Yi, L. Qin, P. Clark, N. C. Kirkiles-Smith, P. Abrahimi, J. Devalliere, G. Moeckel, S. Kulkarni, et al. 2013. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kB signaling in endothelial cells. Circulation 128: 2504-2516.
38. + endosomes. Proc. Natl. Acad. Sci. USA 112: 9686-9691.
39. Klos, A., A. J. Tenner, K. O. Johswich, R. R. Ager, E. S. Reis, and J. Köhl. 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46: 2753-2766.
40. Platt, J. L., A. P. Dalmasso, B. J. Lindman, N. S. Ihrcke, and F. H. Bach. 1991. The role of C5a and antibody in the release of heparan sulfate from endothelial cells. Eur. J. Immunol. 21: 2887-2890.
41. Laudes, I. J., J. C. Chu, M. Huber-Lang, R. F. Guo, N. C. Riedemann, J. V. Sarma, F. Mahdi, H. S. Murphy, C. Speyer, K. T. Lu, et al. 2002. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169: 5962-5970.
42. Yamakuchi, M., N. C. Kirkiles-Smith, M. Ferlito, S. J. Cameron, C. Bao, K. Fox-Talbot, B. A. Wasowska, W. M. Baldwin, III, J. S. Pober, and C. J. Lowenstein. 2007. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc. Natl. Acad. Sci. USA 104: 1301-1306.
43. Vieyra, M., S. Leisman, H. Raedler, W. H. Kwan, M. Yang, M. G. Strainic, M. E. Medof, and P. S. Heeger. 2011. Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection. Am. J. Pathol. 179: 766-774.
44. Gueler, F., S. Rong, W. Gwinner, M. Mengel, V. Bröcker, S. Schön, T. F. Greten, H. Hawlisch, T. Polakowski, K. Schnatbaum, et al. 2008. Complement 5a receptor inhibition improves renal allograft survival. J. Am. Soc. Nephrol. 19: 2302-2312.
45. Dempsey, P. W., M. E. Allison, S. Akkaraju, C. C. Goodnow, and D. T. Fearon. 1996. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271: 348-350.
46. Fuquay, R., B. Renner, L. Kulik, J. W. McCullough, C. Amura, D. Strassheim, R. Pelanda, R. Torres, and J. M. Thurman. 2013. Renal ischemia-reperfusion injury amplifies the humoral immune response. J. Am. Soc. Nephrol. 24: 1063-1072.
47. Park, W. D., J. P. Grande, D. Ninova, K. A. Nath, J. L. Platt, J. M. Gloor, and M. D. Stegall. 2003. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am. J. Transplant. 3: 952-960.
48. Shibata, T., F. G. Cosio, and D. J. Birmingham. 1991. Complement activation induces the expression of decay-accelerating factor on human mesangial cells. J. Immunol. 147: 3901-3908.
49. Collins, A. B., E. E. Schneeberger, M. A. Pascual, S. L. Saidman, W. W. Williams, N. Tolkoff-Rubin, A. B. Cosimi, and R. B. Colvin. 1999. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J. Am. Soc. Nephrol. 10: 2208-2214.
50. Crespo-Leiro, M. G., A. Veiga-Barreiro, N. Doménech, M. J. Paniagua, P. Pinón, M. González-Cuesta, E. Vázquez-Martul, C. Ramirez, J. J. Cuenca, and A. Castro-Beiras. 2005. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am. J. Transplant. 5: 2560-2564.
51. Tan, C. D., G. G. Sokos, D. J. Pidwell, N. G. Smedira, G. V. Gonzalez-Stawinski, D. O. Taylor, R. C. Starling, and E. R. Rodriguez. 2009. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am. J. Transplant. 9: 2075-2084.
52. Sund, S., T. Hovig, A. V. Reisaeter, H. Scott, Ø. Bentdal, and T. E. Mollnes. 2003. Complement activation in early protocol kidney graft biopsies after living-donor transplantation. Transplantation 75: 1204-1213.
53. Haas, M., D. L. Segev, L. C. Racusen, S. M. Bagnasco, J. E. Locke, D. S. Warren, C. E. Simpkins, D. Lepley, K. E. King, E. S. Kraus, and R. A. Montgomery. 2009. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J. Am. Soc. Nephrol. 20: 197-204.
54. Glanville, A. R. 2010. Antibody-mediated rejection in lung transplantation: myth or reality? J. Heart Lung Transplant. 29: 395-400.
55. Magro, C. M., A. Pope Harman, D. Klinger, C. Orosz, P. Adams, J. Waldman, D. Knight, M. Kelsey, and P. Ross, Jr. 2003. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am. J. Transplant. 3: 1143-1154.
56. Neil, D. A., and S. G. Hübscher. 2010. Current views on rejection pathology in liver transplantation. Transpl. Int. 23: 971-983.
57. Koch, C. A., A. Kanazawa, R. Nishitai, B. E. Knudsen, K. Ogata, T. B. Plummer, K. Butters, and J. L. Platt. 2005. Intrinsic resistance of hepatocytes to complement-mediated injury. J. Immunol. 174: 7302-7309.
58. Ollert, M. W., J. V. Kadlec, K. David, E. C. Petrella, R. Bredehorst, and C. W. Vogel. 1994. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J. Immunol. 153: 2213-2221.
59. Haas, M., M. H. Rahman, L. C. Racusen, E. S. Kraus, S. M. Bagnasco, D. L. Segev, C. E. Simpkins, D. S. Warren, K. E. King, A. A. Zachary, and R. A. Montgomery. 2006. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: correlation with histologic findings. Am. J. Trans plant. 6: 1829-1840.
60. Rodriguez, E. R., D. V. Skojec, C. D. Tan, A. A. Zachary, E. K. Kasper, J. V. Conte, and W. M. Baldwin, III. 2005. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am. J. Transplant. 5: 2778-2785.
61. Sis, B., and P. F. Halloran. 2010. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr. Opin. Organ Transplant. 15: 42-48.
62. Loupy, A., G. S. Hill, C. Suberbielle, D. Charron, D. Anglicheau, J. Zuber, M. O. Timsit, J. P. Duong, P. Bruneval, D. Vernerey, et al. 2011. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am. J. Transplant. 11: 56-65.
63. Sis, B., P. M. Campbell, T. Mueller, C. Hunter, S. M. Cockfield, J. Cruz, C. Meng, D. Wishart, K. Solez, and P. F. Halloran. 2007. Transplant glomer-ulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allo-graft biopsies for cause. Am. J. Transplant. 7: 1743-1752.
64. Zhang, X., and E. F. Reed. 2009. Effect of antibodies on endothelium. Am. J. Transplant. 9: 2459-2465.
65. Lee, C. Y., S. Lotfi-Emran, M. Erdinc, K. Murata, E. Velidedeoglu, K. Fox-Talbot, J. Liu, J. Garyu, W. M. Baldwin, III, and B. A. Wasowska. 2007. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation 84: 1324-1334.
66. Hirohashi, T., C. M. Chase, P. Della Pelle, D. Sebastian, A. Alessandrini, J. C. Madsen, P. S. Russell, and R. B. Colvin. 2012. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant. 12: 313-321.
67. Haas, M., and J. Mirocha. 2011. Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am. J. Transplant. 11: 2123-2131.
68. Konvalinka, A., and K. Tinckam. 2015. Utility of HLA antibody testing in kidney transplantation. J. Am. Soc. Nephrol. 26: 1489-1502.
69. Horsburgh, T., S. Martin, and A. J. Robson. 2000. The application of flow cytometry to histocompatibility testing. Transpl. Immunol. 8: 3-15.
70. Pei, R., J. H. Lee, N. J. Shih, M. Chen, and P. I. Terasaki. 2003. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75: 43-49.
71. Sumitran-Karuppan, S., and E. Moller. 1996. The use of magnetic beads coated with soluble HLA class I or class II proteins in antibody screening and for specificity determinations of donor-reactive antibodies. Transplantation 61: 1539-1545.
72. Pei, R., G. Wang, C. Tarsitani, S. Rojo, T. Chen, S. Takemura, A. Liu, and J. Lee. 1998. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum. Immunol. 59: 313-322.
73. Otten, H. G., M. C. Verhaar, H. P. Borst, R. J. Hené, and A. D. van Zuilen. 2012. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. Am. J. Transplant. 12: 1618-1623.
74. Dunn, T. B., H. Noreen, K. Gillingham, D. Maurer, O. G. Ozturk, T. L. Pruett, R. A. Bray, H. M. Gebel, and A. J. Matas. 2011. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am. J. Transplant. 11: 2132-2143.
75. Amico, P., P. Hirt-Minkowski, G. Hönger, L. Gürke, M. J. Mihatsch, J. Steiger, H. Hopfer, and S. Schaub. 2011. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl. Int. 24: 560-569.
76. Lefaucheur, C., A. Loupy, G. S. Hill, J. Andrade, D. Nochy, C. Antoine, C. Gautreau, D. Charron, D. Glotz, and C. Suberbielle-Boissel. 2010. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21: 1398-1406.
77. Tait, B. D., C. Süsal, H. M. Gebel, P. W. Nickerson, A. A. Zachary, F. H. Claas, E. F. Reed, R. A. Bray, P. Campbell, J. R. Chapman, et al. 2013. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95: 19-47.
78. Amico, P., G. Hönger, M. Mayr, J. Steiger, H. Hopfer, and S. Schaub. 2009. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87: 1681-1688.
79. Süsal, C., J. Ovens, K. Mahmoud, B. Döhler, S. Scherer, A. Ruhenstroth, T. H. Tran, A. Heinold, and G. Opelz. 2011. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 91: 883-887.
80. Chen, G., F. Sequeira, and D. B. Tyan. 2011. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immuno-globulin G strength on single antigen beads. Hum. Immunol. 72: 849-858.
81. Sicard, A., S. Ducreux, M. Rabeyrin, L. Couzi, B. McGregor, L. Badet, J. Y. Scoazec, T. Bachelet, S. Lepreux, J. Visentin, et al. 2015. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J. Am. Soc. Nephrol. 26: 457-467.
82. Lachmann, N., K. Todorova, H. Schulze, and C. Schönemann. 2013. Systematic comparison of four cell-and Luminex-based methods for assessment of complement-activating HLA antibodies. Transplantation 95: 694-700.
83. Wahrmann, M., M. Exner, B. Haidbauer, M. Schillinger, H. Regele, G. Körmöczi, and G. A. Böhmig. 2005. [C4d]FlowPRA screening - A specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum. Immunol. 66: 526-534.
84. Bartel, G., M. Wahrmann, M. Exner, H. Regele, N. Huttary, M. Schillinger, G. F. Körmöczi, W. H. Hörl, and G. A. Böhmig. 2008. In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Am. J. Transplant. 8: 41-49.
85. Rose, M. L., and J. D. Smith. 2009. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum. Immunol. 70: 605-609.
86. Wahrmann, M., G. Bartel, M. Exner, H. Regele, G. F. Körmöczi, G. F. Fischer, and G. A. Böhmig. 2009. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl. Int. 22: 982-989.
87. Loupy, A., C. Lefaucheur, D. Vernerey, C. Prugger, J. P. Duong van Huyen, N. Mooney, C. Suberbielle, V. Frémeaux-Bacchi, A. Méjean, F. Desgrandchamps, et al. 2013. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 369: 1215-1226.
88. Crespo, M., A. Torio, V. Mas, D. Redondo, M. J. Pérez-Sáez, M. Mir, A. Faura, R. Guerra, O. Montes-Ares, M. D. Checa, and J. Pascual. 2013. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl. Immunol. 29: 28-33.
89. Lefaucheur, C., D. Viglietti, C. Bentlejewski, J. P. Duong van Huyen, D. Vernerey, O. Aubert, J. Verine, X. Jouven, C. Legendre, D. Glotz, et al. 2015. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J. Am. Soc. Nephrol. DOI: 10.1681/ASN.2014111120.
90. Schaub, S., G. Hönger, M. T. Koller, R. Liwski, and P. Amico. 2014. Determinants of C1q binding in the single antigen bead assay. Transplantation 98: 387-393.
91. Yell, M., B. L. Muth, D. B. Kaufman, A. Djamali, and T. M. Ellis. 2015. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 99: 1151-1155.
92. Locke, J. E., C. M. Magro, A. L. Singer, D. L. Segev, M. Haas, A. T. Hillel, K. E. King, E. Kraus, L. M. Lees, J. K. Melancon, et al. 2009. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am. J. Transplant. 9: 231-235.
93. Kocak, B., E. Arpali, E. Demiralp, B. Yelken, C. Karatas, S. Gorcin, N. Gorgulu, M. Uzunalan, A. Turkmen, and M. Kalayoglu. 2013. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant. Proc. 45: 1022-1025.
94. Orandi, B. J., A. A. Zachary, N. N. Dagher, S. M. Bagnasco, J. M. Garonzik-Wang, K. J. Van Arendonk, N. Gupta, B. E. Lonze, N. Alachkar, E. S. Kraus, et al. 2014. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98: 857-863.
95. Biglarnia, A. R., B. Nilsson, T. Nilsson, B. von Zur-Mühlen, M. Wagner, C. Berne, A. Wanders, A. Magnusson, and G. Tufveson. 2011. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl. Int. 24: e61-e66.
96. Irving, C. A., A. R. Gennery, V. Carter, J. P. Wallis, A. Hasan, M. Griselli, and R. Kirk. 2015. ABO-incompatible cardiac transplantation in pediatric patients with high isohemagglutinin titers. J. Heart Lung Transplant. 34: 1095-1102.
97. Dawson, K. L., A. Parulekar, and H. Seethamraju. 2012. Treatment of hyperacute antibody-mediated lung allograft rejection with eculizumab. J. Heart Lung Transplant. 31: 1325-1326.
98. Fan, J., P. Tryphonopoulos, A. Tekin, S. Nishida, G. Selvaggi, A. Amador, J. Jebrock, D. Weppler, D. Levi, R. Vianna, et al. 2015. Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient. Am. J. Transplant. 15: 1995-2000.
99. Stegall, M. D., T. Diwan, S. Raghavaiah, L. D. Cornell, J. Burns, P. G. Dean, F. G. Cosio, M. J. Gandhi, W. Kremers, and J. M. Gloor. 2011. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11: 2405-2413.
100. Cornell, L. D., C. A. Schinstock, M. J. Gandhi, W. K. Kremers, and M. D. Stegall. 2015. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am. J. Transplant. 15: 1293-1302.
101. Bentall, A., D. B. Tyan, F. Sequeira, M. J. Everly, M. J. Gandhi, L. D. Cornell, H. Li, N. A. Henderson, S. Raghavaiah, J. L. Winters, et al. 2014. Antibody-mediated rejection despite inhibition of terminal complement. Transpl. Int. 27: 1235-1243.
102. Burbach, M., C. Suberbielle, I. Brochériou, C. Ridel, L. Mesnard, K. Dahan, E. Rondeau, and A. Hertig. 2014. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 98: 1056-1059.
103. Ricklin, D., and J. D. Lambris. 2013. Progress and trends in complement therapeutics. Adv. Exp. Med. Biol. 735: 1-22.doi:10.1007/978-1-4614-4118-2-1
104. Tillou, X., N. Poirier, S. Le Bas-Bernardet, J. Hervouet, D. Minault, K. Renaudin, F. Vistoli, G. Karam, M. Daha, J. P. Soulillou, and G. Blancho. 2010. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int. 78: 152-159.
105. Vo, A. A., A. Zeevi, J. Choi, K. Cisneros, M. Toyoda, J. Kahwaji, A. Peng, R. Villicana, D. Puliyanda, N. Reinsmoen, et al. 2015. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99: 299-308.
106. Pratt, J. R., M. E. Jones, J. Dong, W. Zhou, P. Chowdhury, R. A. Smith, and S. H. Sacks. 2003. Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/reperfusion damage, acute rejection, and chronic nephropathy. Am. J. Pathol. 163: 1457-1465.
107. Serkova, N. J., B. Renner, B. A. Larsen, C. R. Stoldt, K. M. Hasebroock, E. L. Bradshaw-Pierce, V. M. Holers, and J. M. Thurman. 2010. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 255: 517-526.